13.02.2014
Carl Zeiss Meditec AG DE0005313704
DGAP-News: Carl Zeiss Meditec AG: cautious start to the new financial year, after strong annual results
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarter Results
Carl Zeiss Meditec AG: cautious start to the new financial year, after
strong annual results
13.02.2014 / 07:00
---------------------------------------------------------------------
Carl Zeiss Meditec AG: cautious start to the new financial year, after
strong annual results
Negative currency effects hinder growth in the first quarter
JENA, 13 February 2014
As a result of unfavourable exchange rates and a slowdown in momentum in
Microsurgery, Carl Zeiss Meditec AG ended the first quarter of financial
year 2013/2014 with a slight decline in revenue and earnings. At EUR 212.3
million, revenue was 3.1 percent lower than in the same quarter of the
previous year (adjusted for currency effects: +1.7%); earnings before
interest and taxes fell to EUR 26.5 million (previous year: EUR 31.3
million).
In the first three months of the new financial year, foreign currency
losses and a smaller share of revenue generated by the Microsurgery SBU
noticeably contributed to the lower operating results recorded by the
medical technology provider compared with the same quarter of the previous
year. Development of the strategic business units (SBUs) and regions during
the first quarter was mixed.
Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, gave his take
on the 3-month figures: 'In spite of a more restrained pace of growth in
Microsurgery and the negative currency effects, which were the main cause
of the slowdown in growth, our sights for the financial year remain firmly
set on our goal to increase revenue at least on a par with general market
growth; our objective to sustainably increase our EBIT margin to 15 percent
by 2015 also remains unchanged.'
Revenue by business unit
The development of business in our strategic business units was varied. The
more restrained pace of growth seen recently in Microsurgery was further
curbed by negative currency effects.
Revenue decreased year-on-year from EUR 105.1 million to EUR 92.1 million.
The SBU Ophthalmic Systems grew slightly, in spite of the strong
competitive pressure and an unfavourable currency effect. Revenue increased
year-on-year from EUR 84.4 million to EUR 86.7 million. Once again, the
Surgical Ophthalmology SBU performed extremely well. Revenue climbed to EUR
33.4 million, compared with EUR 29.5 million in the same quarter of the
previous year.
Revenue by region
The EMEA region (Europe, Middle East and Africa) generated revenue of EUR
70.5 million (previous year: EUR 76.2 million). This reflects in particular
the expiry of government investment schemes in Russia, which had had a
particularly positive effect on this region's revenue in the previous
quarters.
The development of business in the Americas region was very positive
compared with the previous year. Revenue here increased by 6.3 percent
year-on-year, to EUR 77.6 million. Both the USA and Latin America
contributed to growth in this region.
Business in the Asia/Pacific region was once again significantly impacted
by currency effects. A positive development of business, particularly in
China and Southeast Asia, was not enough to compensate for the weak
Japanese yen, in particular, combined with a general slowdown in economic
growth in Japan. At EUR 64.2 million, revenue in this region was down by
8.1 percent compared with the previous year. Adjusted for currency effects,
however, the region would have reported growth of almost 3 percent.
Outlook
In spite of difficult general conditions, Ludwin Monz believes the Company
is on the right track. 'We shall continue to adhere firmly to our
investments in R&D, which form the basis for future growth. Strategic
foundations, such as the consolidation of our rapidly growing intraocular
lens business through the acquisition of Aaren Scientific and the
improvement of our market penetration in Turkey, which we announced at the
beginning of 2014, support our aim to achieve a regionally balanced market
focus geared to a wide range of growth areas.'
Revenue by strategic business unit
Figures in EUR '000 3 Months 3 Months Change from previous year 2012/2013 2013/2014 Ophthalmic Systems 84,421 86,738 + 2.7% Surgical Ophthalmology 29,472 33,438 + 13.5% Microsurgery 105,106 92.103 - 12.4%Revenue by region Figures in EUR '000 3 Months 3 Months Change from previous year 2012/2013 2013/2014 EMEA 76,209 70,522 -7.5% Americas 72,973 77,568 + 6.3% Asia/Pacific region 69,817 64,189 -8.1%Press contact: Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG Phone+49 (0)3641 220-331, E-Mail: [email protected] Investors contact: Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG Phone: +49 (0)3641 220-116, E-Mail: [email protected] www.meditec.zeiss.de/presse End of Corporate News --------------------------------------------------------------------- 13.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Carl Zeiss Meditec AG Göschwitzer Str. 51-52 07745 Jena Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: [email protected],[email protected] Internet: www.meditec.zeiss.de ISIN: DE0005313704 WKN: 531370 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 252409 13.02.2014
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Carl Zeiss Meditec AG ISIN: DE0005313704 können Sie bei EQS abrufen
Medtech , 531370 , AFX , XETR:AFX